BIOMARKERS OF DISEASE PROGRESSION IN ASIAN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS TREATED WITH NINTEDANIB: SUBGROUP ANALYSIS OF THE INMARK TRIAL

Abstract

index (BMI) and lung function (forced vital capacity, total lung capacity) at baseline, more frequent pneumothorax and pneumomediastinum, higher decline rates in lung function, and poorer prognosis during follow-up than the no-PPFE group. PPFE was an independent risk factor (hazard ratio = 2.953, 95% confidence interval: 1.350-6.460, P = 0.007) for pneumothorax or pneumomediastinum, but not for mortality in patients with IPF. Conclusions: Among patients with IPF, compared to the no-PPFE group, the PPFE group showed lower BMI and lung function and showed more frequent complications and poorer survival during follow-up.